louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02450864: The Biological Effect of ESWT and the Role of Proinflammatory Cytokines and Cannabinoid Receptor in Shoulder Stiffness
Official title: The Biological Effect of Extracorporeal Shockwave Technology (ESWT) and the Role of Proinflammatory Cytokines and Cannabinoid Receptor in Shoulder Stiffness
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stiffness of Shoulder, Not Elsewhere Classified
Keywords: Stiffness of Shoulder, Not Elsewhere Classified
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2015-05-21
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Investigators recent data showed anti-inflammatory effect of Effect of Extracorporeal Shockwave Technology (ESWT). Little studies focused on the effect and pathomechanism of ESWT on shoulder stiffness.

Detailed description: 1. First year:Investigators intend to further delineate the inflammatory mechanism, such as IL-1β, CB1, HSP in the incidence of shoulder stiffness.
2. Second year: Investigators intend to conduct a prospective randomized double-blind study for the clinical effect of ESWT on patients with shoulder stiffness.
3. Third year: Investigators wish to test the biologic effect of ESWT on patients with shoulder stiffness and to elucidate the molecular mechanism for this effect through a randomized comparative study.

Eligibility criteria: Inclusion Criteria:

* aged 18 to 80 years
* receiving surgery for open acromioplasty

Exclusion Criteria:

* shoulder disorders caused by traumatic fracture
* previous surgery
* osteoarthritis
* malignant disorders
* hepatic disorders
* renal disorders

Primary outcomes:
measure: the range of motion (ROM) of the shoulder as a measure
timeFrame: 1weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung city
country: Taiwan
facility: Chang Gung Memorial Hospital
Study officials:
affiliation: Chang Gung Memorial Hospital
name: Jih-Yang Jih-Yang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04091464: TRAIN-BW: Backward Walking Training in Multiple Sclerosis
Official title: TRAIN-BW: Backward Walking Training in Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Multiple Sclerosis
Gait Disorders, Neurologic
Accidental Fall
Keywords: Backward Walking
Neurorehabilitation
Lead sponsor: Wayne State University
Sponsor class: OTHER
First posted: 2019-09-16
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Individuals with multiple sclerosis (MS) experience in impairments in mobility and cognition that increase the risk for accidental falls. More than 50% of individuals with MS experience injurious falls within a 6-month period. Current interventions to improve fall risk have focused on forward walking (FW) and balance training, resulting in small declines in the relative risk for falls with a large degree of variability. Interestingly, motor differences between MS and healthy controls are more pronounced in backward walking (BW), yet no studies have investigated BW training as an intervention to reduce fall risk in persons with MS. This study will investigate the feasibility, acceptability and impact of BW training compared to forward walking training on motor function and fall risk in persons with MS.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of MS
* PDDS \<6, indicating ability to ambulate with or without an assistive device \>/= 50% of the time
* Self-reported walking dysfunction as evidenced by a score of \>/= 30 on MSWS-12 OR reports of 2 or more falls in the prior 6 months, indicating a frequent faller.

Exclusion Criteria:

* MS relapse within the past 30 days
* comorbid neurological disorder
* acute orthopedic disorder/injury
* unable to follow study-related commands

Primary outcomes:
measure: Sway during quiet stance
timeFrame: Change in sway at 8 weeks
measure: Stepping latency on push-and-release test
timeFrame: Change in stepping latency at 8 weeks
Secondary outcomes:
measure: Client Satisfaction Questionnaire (CSQ-8)
timeFrame: 8 weeks
measure: Patient Global Impression of Change
timeFrame: 8 weeks
measure: Number of Active Minutes
timeFrame: Change in Physical Activity measures at 8 weeks
measure: Number of Falls
timeFrame: 6 months
measure: Forward and Backward Velocity and Double Support Time
timeFrame: Change in velocity and double support time at 8 weeks
measure: ABC Scale
timeFrame: Change in balance confidence at 8 weeks
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Wayne State University
state: Michigan
Study officials:
affiliation: Wayne State University
name: Nora Fritz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00779064: BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
Official title: BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atrial Fibrillation
Keywords: Atrial Fibrillation
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2008-10-24
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).


Eligibility criteria: Inclusion Criteria:

* 20 years or older
* Japanese male or female
* Non- valvular atrial fibrillation documented by ECG
* Patients aged 60 years and older or with a risk of stroke

Exclusion Criteria:

* Prior stroke and TIA
* Patients in whom anticoagulants are contraindicated

Primary outcomes:
measure: Pharmacokinetics (PK) CL/f, AUC, Cmax, Pharmacodynamics (PD), Factor Xa activity, PT, PT-INR, aPTT and HEPTEST(R)
timeFrame: Day 14 and 28
Secondary outcomes:
measure: Each category of bleeding events and adverse event
timeFrame: Throughout treatment and followup period
Other outcomes:
Locations:
city: Kitakyushu
country: Japan
state: Fukuoka
city: Kurume
country: Japan
state: Fukuoka
city: Onga
country: Japan
state: Fukuoka
city: Kitahiroshima
country: Japan
state: Hokkaido
city: Amagasaki
country: Japan
state: Hyogo
city: Kawachinagano
country: Japan
state: Osaka
city: Suita
country: Japan
state: Osaka
city: Fukuoka
country: Japan
city: Fukuoka
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
city: Osaka
country: Japan
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT03349164: Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region
Official title: Local Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Thromboembolic Pulmonary Hypertension
Lead sponsor: Novosibirsk Scientific Research Institute for Circulatory Pathology
Sponsor class: OTHER
First posted: 2017-11-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients are survivors after acute PE. Than they should intake anticoagulation treatment at least 3-4 month. Then they will be assessed clinically by local cardiologists, echocardiography and VQ scan will be performed.

Brief summary: There will be assessment of patients after acute pulmonary embolism for the development of CTEPH

Detailed description: There will be assessment of patients after acute pulmonary embolism for the development of CTEPH.

There will be analysis of case histories of 40 patients with acute pulmonary embolism. All this patients will be clinically assessed by local cardiologist. Also echocardiography, lung VQ scans (perfusion and ventilation) will be performed.

Patients with chronic thromboembolic pulmonary hypertension will be assessed by local team experienced in CTEPH treatment.

Eligibility criteria: Inclusion Criteria:

* patients who had episodes of acute pulmonary embolism
* 3-4 months of anticoagulation treatment after acute pulmonary embolism
* informed consent

Exclusion Criteria:

* pregnancy

Primary outcomes:
measure: clinical presentation of chronic thromboembolic pulmonary hypertension
timeFrame: 3-4 month after acute pulmonary embolism
measure: clinical presentation of chronic thromboembolic pulmonary hypertension
timeFrame: 3-4 month after acute pulmonary embolism
Secondary outcomes:
measure: presence of pulmonary hypertension - mean pulmonary artery pressure > 25 mm Hg according to echocardiography
timeFrame: 3-4 month after acute pulmonary embolism
measure: presence of perfusion deficit in pulmonary artery according to VQ scan
timeFrame: 3-4 month after acute pulmonary embolism
Other outcomes:
Locations:
city: Novosibirsk
country: Russian Federation
facility: Novosibirsk research institute of circulation pathology
state: Novosibirskaya Oblast'
Study officials:
References:
Clinical trial NCT05754164: Attention Control Training for the Prevention of PTSD in Firefighters
Official title: Attention Control Training for the Prevention of PTSD in Firefighters
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: PTSD
Keywords: PTSD
Attention Control Training
Lead sponsor: Adai Technology (Beijing) Co., Ltd.
Sponsor class: OTHER
Collaborators: name: Kungming Training Corps of National Fire and Rescue Administration
First posted: 2023-03-03
Enrollment: 180
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aimed to examine the effect of Attention Control Training (ACT) intervention on reducing PTSD symptoms in firefighters. The study was a randomized controlled trial carried out in Kunming, China, and involved the recruitment of 180 active firefighters as participants. The intervention lasted for an 8-week duration, during which participants participated in ACT exercises delivered through a smartphone application.


Eligibility criteria: Inclusion Criteria:

* being an active firefighter and aged between 18 and 50
* with no history of severe PTSD

Exclusion Criteria:

* having suicidal ideation or intent
* having an active psychotic disorder other than PTSD
* prior participation in a cognitive-behavioral intervention
* concurrent participation in another study.

Primary outcomes:
measure: Posttraumatic Stress Disorder Checklist-Civilian Version
timeFrame: Baseline
measure: Posttraumatic Stress Disorder Checklist-Civilian Version
timeFrame: Immediately Post-intervention
measure: Patient Health Questionnaire-9
timeFrame: Baseline
measure: Patient Health Questionnaire-9
timeFrame: Immediately Post-intervention
measure: Generalized Anxiety Disorder 7-item scale
timeFrame: Baseline
measure: Generalized Anxiety Disorder 7-item scale
timeFrame: Immediately Post-intervention
measure: Attention Bias Score
timeFrame: Baseline
measure: Attention Bias Score
timeFrame: Immediately Post-Intervention
measure: Attention Bias Variability
timeFrame: Baseline
measure: Attention Bias Variability
timeFrame: Immediately Post-Intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Kunming
country: China
facility: Kunming Training Corps of the National Fire and Rescue Administration
state: Yunnan
Study officials:
References:
Clinical trial NCT05825664: Underwater Versus Conventional Endoscopic Mucosal Resection in the Treatment of Non-pedunculated Colorectal Polyps
Official title: Comparison of the Efficiency and Safety of Underwater Endoscopic Mucosal Resection and Conventional Endoscopic Mucosal Resection in the Treatment of Non-pedunculated Colorectal Polyps
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Colorectal Polyp
Colorectal Neoplasms
Keywords: colorectal polyp
underwater endoscopic mucosal resection
conventional endoscopic mucosal resection
Lead sponsor: University of Medicine and Pharmacy at Ho Chi Minh City
Sponsor class: OTHER
First posted: 2023-04-24
Enrollment: 228
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A prospective, randomized, controlled study to compare the efficacy and safety of underwater endoscopic mucosal resection and conventional endoscopic mucosal resection in removal of non-pedunculated colorectal polyps

Detailed description: * Patients are undergone colonoscopy at the Endoscopy department of Ho Chi Minh City University Medical Center.
* Randomize patients with non-pedunculated polyp of 10mm or larger in size into 2 interventional groups based on Random function of Statistical Package for the Social Sciences (SPSS) 20.0, including (1) Group 1: Underwater endoscopic mucosal resection (UEMR) and (2) Group 2: Conventional endoscopic mucosal resection (CEMR).
* The time of local recurrence assessment depends on the histopathology of polyps. Polyps with low grade dysplasia are followed up at 6 months, while polyps with high grade dysplasia are followed at 3 months.
* Collecting variables which consist of primary and secodary outcomes.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Non-pedunculated polyps of 10 mm or more in size
* Type 1 or 2 according to NBI International Colorectal Endoscopy (NICE) classification
* Patients must sign an informed consent form prior to registration in study

Exclusion Criteria:

* Lesions with signs of deep invasion (hard, friable tissue, poor mobility, positive "non-lifting" sign)
* Type 3 according to NICE classification
* Colorectal cancer
* Patients with unstable chronic disease (melitus diabetes, hypertension, heart failure, kidney failure, liver failure, chronic obstructive pulmonary disease)
* Hemostasis disorder (INR \> 1.5; platelets \< 100000/mm3)

Primary outcomes:
measure: en bloc resection
timeFrame: immediately after the procedure
measure: Curative rate
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
measure: Complication rate
timeFrame: up to 2 weeks
measure: Local recurrence rate
timeFrame: 6 months
measure: Procedure time
timeFrame: during the procedure
Other outcomes:
Locations:
city: Ho Chi Minh City
country: Vietnam
facility: University of Medicine and Pharmacy at Ho Chi Minh city
Study officials:
References:
Clinical trial NCT00953264: Hormonal and Metabolic Effects of Weight Loss
Official title: Hormonal and Metabolic Effects of Weight Loss
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2009-08-06
Enrollment: 290
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators here propose to evaluate the hormonal and metabolic effects of weight loss, including evaluation of changes in several tissues.


Eligibility criteria: Inclusion Criteria:

* BMI \> 27 kg/m2 (adults)

Exclusion Criteria:

* pregnancy, breastfeeding
* patients with:

  * heart failure
  * impaired hepatic or renal function
  * anaemia
  * disturbed coagulation
  * infection, malabsorption
  * severe hypertension
  * any other endocrine disorder

Primary outcomes:
measure: hormonal and metabolic changes during weight loss
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charite
Study officials:
References:
Clinical trial NCT01786564: Home Sleep and Circadian Phase: Mediators of Diabetes Risk
Official title: Home Sleep and Circadian Phase: Mediators of Diabetes Risk
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Deprivation
Diabetes
Circadian Dysregulation
Keywords: diabetes
sleep
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2013-02-08
Enrollment: 120
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will recruit a total of 100 African Americans (AA) and 100 non-Hispanic whites (WH) with equal numbers of men and women in each group completing the entire study. Ages will be 21-50 years and body mass indices (BMI) will be \<40 kg/m2.

Brief summary: The purpose of this study is to determine if deficient sleep and/or disruption with the body's internal clock ("circadian rhythms") are associated with diabetes risk. This study is being done to look at the possible relationships between sleep and risk of diabetes by examining sleep in the home and diabetes risk in the laboratory.


Eligibility criteria: Inclusion Criteria:

1. Ages 21-50 years
2. BMI \<40 kg/m2.
3. No major illness.
4. No history of psychiatric, endocrine, cardiac or sleep disorders,
5. Premenopausal, non-pregnant women.
6. Those with dyslipidemia and hypertension will be included if these conditions are controlled by a stable treatment, such as lipid-lowering or antihypertensive medications (except beta blockers).

Exclusion criteria include:

1. Persons with diabetes.
2. Persons with diagnosed sleep disorders or apnea-hypopnea index\>15.
3. History of cardiovascular event or disease (excluding controlled hypertension).
4. Major psychiatric disorder or other major illness.
5. Persons taking medications, including but not limited to antidepressants and hypnotics (but excluding lipid-lowering drugs and anti-hypertensive medications as mentioned above).
6. Persons regularly taking medication that affects melatonin such as beta blockers and exogenous melatonin.
7. Anyone who tests positive for common drugs of abuse.
8. People with color blindness.
9. People who have had Lasik eye surgery.
10. People who work night shifts.
11. Participants who travel across multiple time zones will be studied only after they have remained in the Central Time Zone (or Indiana) for one month prior to the study.

Primary outcomes:
measure: Oral Disposition Index
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
Study officials:
affiliation: Northwestern University
name: Kristen Knuston, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00145964: Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)
Official title: Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Cirrhosis, Biliary
Biliary Cirrhosis, Primary
Keywords: Biliary Cirrhosis, Primary
genes
autoimmune disease
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2005-09-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Primary biliary cirrhosis (PBC) is a disease of the liver, which predominantly affects women. It causes slowly progressive liver disease, which eventually causes liver failure, requiring a liver transplant. Several different studies of large patient cohorts indicate that the cause of this disease is likely due to a combination of factors including genetic and environmental. PBC is associated with several other "autoimmune diseases" - recently a gene has been identified to be abnormal in individuals with another autoimmune liver disease, namely rheumatoid arthritis. This gene usually tells the body when to switch off an immune response. This study plans to identify whether individuals diagnosed with PBC have a similar abnormality in this gene called protein Tyrosine Phosphatase.

Detailed description: Very recently, a single nucleotide polymorphism (SNP) in the PTPN22 gene encoding the Lyp (lymphoid-specific phosphatase) PTP has been shown to be associated with susceptibility to rheumatoid arthritis (RA) and Type 1 diabetes (T1D)4,5. These data are consistent with the known role for Lyp in suppressing T cell activation and with data showing T cell activation (and potentially autoreactivity) to be increased by the RA and T1D-associated PTPN22 variant. The PTPN22 risk allele has also been recently implicated in Grave's disease and as such appears to represent a susceptibility allele for many autoimmune diseases. As a number of these conditions (RA, T1D etc.) frequently occur within members of PBC families, this PTPN22 variant is very likely to also be involved in PBC, a possibility we will directly investigate in this pilot study. The aim of this study is to analyze the frequency of a specific PTPN22 polymorphism in patients with PBC.

Eligibility criteria: Inclusion Criteria:

* patients attending Liver Clinic at Toronto Western Hospital, Toronto, ON, Canada
* AMA positive and liver biopsy proven PBC.

Exclusion Criteria:

- AMA negative PBC

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Liver Clinic, Toronto Western Hospital, UHN.
state: Ontario
Study officials:
affiliation: UHN - Toronto Western Hospital, University of Toronto
name: E.J.L (Jenny) Heathcote, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00229164: The Effect of Transcutaneous Electric Nerve Stimulation on Primary Dysmenorrhea-a Randomized Control Study
Official title: The Effect of Transcutaneous Electric Nerve Stimulation on Primary Dysmenorrhea-a Randomized Control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Primary Dysmenorrhea,
Keywords: Primary Dysmenorrhea,
Transcutaneous Electric Nerve Stimulation
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-29
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effect of high frequency TENS and compare to the placebo effect by sham TENS in a randomized control study.

Detailed description: Over 50% of American women suffered from dysmenorrhea and 10% of them will take sick leave for 1-2 days. Previous randomized control studies have demonstrated the pain relief effect of using high frequency TENS in dysmenorrheal pain. However, no investigation has been conducted to investigate the effect of high frequency TENS in female population in our country. The purpose of this study is to investigate the effect of high frequency TENS and compare to the placebo effect by sham TENS in a randomized control study.

Eligibility criteria: Inclusion Criteria:

* primary Dysmenorrhea

Exclusion Criteria:

* subjects with organic disorders

Primary outcomes:
measure: all measure the pain threshold,
measure: self-rating questionnaire
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University
name: Shwu-Fen Wang, Ph.D
role: STUDY_DIRECTOR
References: